Advances in Anti Rheumatic Therapy
1st Edition
Published on 11. December 1995
Book
Hardback
252 pages
978-0-8493-4937-9 (ISBN)
Description
This work on advances in anti-rheumatic therapy covers topics such as: outcome measures in clinical trials of anti-rheumatic drugs; azapropazone (AZP); the mode of action of glucocorticoids; and clinical trials of oral chondroitin sulphate in the treatment of osteoarthritis.
More details
Language
English
Place of publication
Bosa Roca
United States
Publishing group
Taylor & Francis Inc
Target group
College/higher education
Professional and scholarly
Illustrations
54 s/w Tabellen
54 Tables, black and white
Dimensions
Height: 254 mm
Width: 178 mm
Weight
680 gr
ISBN-13
978-0-8493-4937-9 (9780849349379)
Copyright in bibliographic data and cover images is held by Nielsen Book Services Limited or by the publishers or by their respective licensors: all rights reserved.
Schweitzer Classification
Person
Content
Introduction to advances in anti-rheumatic therapy, K.D. Rainsford; outcome measures in clinical trials of anti-rheumatic drugs, N. Bellamy et al; the elderly as the main group for therapy with anti-rheumatic drugs - problems and strategies, R. Jones and S. Betmouni; changing views on the approach to rehabilitation and outcome evaluation in rheumatoid arthritis in the light of recent advances in cognitive psychology, K. Berglund et al; mode of action, uses and side effects of anti-inflammatory drugs, K.D. Rainsford; clinical development of an NSAID combined with a prostaglandin E analogue, A. Karim and G.S. Geis; azapropazone (AZP) - the new therapeutic indications for an established drug, demonstration of antineutrophil effects in various animal models and in humans, S.A. Mousa et al; recent advances in the understanding of the mode of action of glucorticoids, J. Garcia-Leme; the rheumatoid arthritis azathioprine registry - an update, A.R. Hickey and M.B Urowitz; Subreum (OM-8980) and rheumatoid arthritis - a novel immunomodulating drug from natural product developments, J.C. Farine and M. Meredith; clinical trials of oral chondroitin sulphate in the treatment of osteoarthritis, E. Vignon; Zileuton (ABT-077) - a novel 5-lipoxygenase inhibitor, S.R. Brandwein and P. Rubin; selective monoclonal antibodies for therapy of rheumatic diseases, R. Watts and B.L. Hazleman; dietary polyunaturated fatty acids as natural therapeutic rationales in rheumatoid arthritis, J.M. Kremer.